Enzon Pharmaceuticals (ENZN) 10-K2017 FY Annual report

Filed: 21 Mar 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: added, ASUNo, auditor, awaiting, Chile, Clarifying, deducted, devote, entrance, error, formatted, fraud, fromNektar, fully, inaccuracy, inappropriate, lapsed, leaving, MTC, orany, PCAOB, prejudice, President, provisional, regular, remeasurement, replaced, satisfiedall, Schering, sharp, Shire, theentrance, theFASB, theregistration, unexercised, XBRL

Removed: Abelcet, absorption, acceptance, Adagen, adalimumab, advisor, Affymax, agency, analytical, animal, announcement, assessing, assigned, auditing, baseline, biological, calendar, carried, case, cGMP, chemistry, civil, commercialize, commercially, comply, conducting, confidentiality, conserving, contracting, criminal, data, declined, degree, demonstrate, DepoCyt, derive, description, designing, diverted, dosage, dose, employment, end, enter, establishment, etanercept, examination, excretion, expanded, export, facilitate, formulation, gain, goal, golimumab, good, healthy, incremental, IND, infliximab, initially, injunctive, intense, international, introducing, investigational, laboratory, largest, legally, lesser, liable, list, LNA, manufacturer, maximizing, metabolism, noncompliance, official, open, optimal, oversee, par, patient, periodically, Phase, pill, poison, population, potency, power, preliminary, prescribed, preserve, pressure, production, purity, pursue, reallocated, register, registering, relate, represented, returned, reversed, satisfaction, sequential, shipment, shipped, sigma, spend, split, stability, strategic, studied, sublicensed, submission, submitting, supporting, suspension, Takeda, targeted, tau, technical, technological, tested, tolerance, trial, twelve, unaffected, undisclosed, unused

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ENZN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Enzon Pharmaceuticals, Inc. (the Company) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Andrew Rackear, Chief Executive Officer and Secretary of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 21, 2018	/s/ Andrew Rackear
	Andrew Rackear
	Chief Executive Officer and Secretary
	(Principal Executive Officer)

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Enzon Pharmaceuticals, Inc. and will be furnished to the Securities Exchange Commission or its staff upon request.